Kinnate Biopharma Analysis
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Kinnate Biopharma is overvalued with Real Value of 2.71 and Hype Value of 2.96. The main objective of Kinnate Biopharma delisted stock analysis is to determine its intrinsic value, which is an estimate of what Kinnate Biopharma is worth, separate from its market price. There are two main types of Kinnate Biopharma's stock analysis: fundamental analysis and technical analysis.
The Kinnate Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Kinnate Biopharma's ongoing operational relationships across important fundamental and technical indicators.
Kinnate |
Kinnate Stock Analysis Notes
About 83.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.79. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kinnate Biopharma recorded a loss per share of 2.78. The entity had not issued any dividends in recent years. Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. Kinnate Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people. To find out more about Kinnate Biopharma contact Nima MBA at 858 299 4699 or learn more at https://www.kinnate.com.Kinnate Biopharma Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kinnate Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kinnate Biopharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Kinnate Biopharma is not yet fully synchronised with the market data | |
| Kinnate Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (112.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kinnate Biopharma currently holds about 262.42 M in cash with (100.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are owned by institutional investors |
Kinnate Biopharma Upcoming and Recent Events
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Kinnate Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 124.99 M.Kinnate Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kinnate Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kinnate Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kinnate Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kinnate Biopharma Outstanding Bonds
Kinnate Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kinnate Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kinnate bonds can be classified according to their maturity, which is the date when Kinnate Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Kinnate Biopharma Predictive Daily Indicators
Kinnate Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kinnate Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Kinnate Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Kinnate Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kinnate shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Kinnate Biopharma. By using and applying Kinnate Stock analysis, traders can create a robust methodology for identifying Kinnate entry and exit points for their positions.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. Kinnate Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Kinnate Biopharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |